What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Chemotherapy
The scientist’s investigation covers issues in Internal medicine, Surgery, Gastroenterology, Chemotherapy and Lymphoma.
His study ties his expertise on Oncology together with the subject of Internal medicine.
His study in Vincristine, Transplantation, Survival rate, Regimen and Cyclophosphamide is carried out as part of his studies in Surgery.
His research in Gastroenterology intersects with topics in Combination chemotherapy, Progressive disease, Cytarabine, Immunology and Pathology.
His work deals with themes such as Follicular phase and Central nervous system disease, which intersect with Chemotherapy.
His Lymphoma study combines topics in areas such as Beta-2 microglobulin, Phases of clinical research, Clinical endpoint, Complication and Staging system.
His most cited work include:
- Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). (532 citations)
- Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia (419 citations)
- Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial (415 citations)
What are the main themes of his work throughout his whole career to date?
Fredrick B. Hagemeister mostly deals with Internal medicine, Surgery, Gastroenterology, Lymphoma and Oncology.
His study in Rituximab, Chemotherapy, Vincristine, Follicular lymphoma and Regimen is done as part of Internal medicine.
His studies in Rituximab integrate themes in fields like Lenalidomide, Mantle cell lymphoma, Neutropenia, Diffuse large B-cell lymphoma and Fludarabine.
He interconnects Progressive disease, Beta-2 microglobulin, Mitoxantrone, Median follow-up and Survival rate in the investigation of issues within Gastroenterology.
His Lymphoma study combines topics from a wide range of disciplines, such as Cancer and Refractory.
His Oncology research is multidisciplinary, incorporating elements of International Prognostic Index, B-cell lymphoma and CD20.
He most often published in these fields:
- Internal medicine (75.06%)
- Surgery (44.52%)
- Gastroenterology (36.13%)
What were the highlights of his more recent work (between 2013-2021)?
- Internal medicine (75.06%)
- Oncology (33.10%)
- Rituximab (32.87%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Internal medicine, Oncology, Rituximab, Lymphoma and Diffuse large B-cell lymphoma.
His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology and Surgery.
His studies deal with areas such as Stage and Cumulative incidence as well as Gastroenterology.
His Oncology study incorporates themes from International Prognostic Index, Refractory, Immunology and Transplantation.
His biological study spans a wide range of topics, including Lenalidomide, Phases of clinical research, Vincristine, Cyclophosphamide and Ibrutinib.
His Lymphoma research is multidisciplinary, relying on both Radiation therapy, Radiology, Adverse effect and Salvage therapy.
Between 2013 and 2021, his most popular works were:
- Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial (415 citations)
- Double hit lymphoma: the MD Anderson Cancer Center clinical experience. (218 citations)
- Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial (176 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Chemotherapy
Fredrick B. Hagemeister spends much of his time researching Internal medicine, Rituximab, Oncology, Surgery and Lymphoma.
Fredrick B. Hagemeister regularly links together related areas like Gastroenterology in his Internal medicine studies.
His work carried out in the field of Rituximab brings together such families of science as Lenalidomide, Phases of clinical research, Tolerability, Ibrutinib and Follicular lymphoma.
His Oncology study incorporates themes from Clinical trial, Refractory, Gemcitabine, Chemotherapy and Bendamustine.
His Surgery research is multidisciplinary, incorporating elements of Cancer and Mantle cell lymphoma.
His Lymphoma research integrates issues from T cell, Radiation therapy and Survival analysis.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
